Email this article Sigma-1 receptor antagonists haloperidol and chlorpromazine modulate the effect of glutoxim on NA+ transport in frog skin
- Authors: Krutetskaya Z.I.1, Melnitskaya A.V.1, Antonov V.G.1, Nozdrachev A.D.1
-
Affiliations:
- Saint-Petersburg State University
- Issue: Vol 484, No 5 (2019)
- Pages: 629-632
- Section: Biochemistry, biophysics, molecular biology
- URL: https://journals.eco-vector.com/0869-5652/article/view/12788
- DOI: https://doi.org/10.31857/S0869-56524845629-632
- ID: 12788
Cite item
Full Text
Abstract
Using voltage-clamp technique, the involvement of sigma-1 receptors in immunomodulatory drug glutoxim regulation of Na+ transport in frog skin was investigated. We have shown for the first time that preincubation of the frog skin with sigma-1 receptor antagonists – haloperidol or chlorpromazine – attenuates the stimulatory effect of glutoxim on Na+ transport. The results suggest the possible involvement of the sigma-1 receptors in glutoxim effect on Na+transport in frog skin epithelium.
Keywords
About the authors
Z. I. Krutetskaya
Saint-Petersburg State University
Author for correspondence.
Email: z.krutetskaya@spbu.ru
Russian Federation, Saint-Petersburg
A. V. Melnitskaya
Saint-Petersburg State University
Email: z.krutetskaya@spbu.ru
Russian Federation, Saint-Petersburg
V. G. Antonov
Saint-Petersburg State University
Email: z.krutetskaya@spbu.ru
Russian Federation, Saint-Petersburg
A. D. Nozdrachev
Saint-Petersburg State University
Email: z.krutetskaya@spbu.ru
Academician of the RAS
Russian Federation, Saint-PetersburgReferences
- Наточин Ю.В. Основы физиологии почки. Л.: Наука, 1982. 184 с.
- Benos D.J., Stanton B.A. // J. Physiol. 1999. V. 520. P. 631–644.
- Kellenberger S., Schild L. // Physiol. Rev. 2002. V. 82. P. 735–767.
- Крутецкая З.И., Лебедев О.Е., Мельницкая А.В., Антонов В.Г., Ноздрачев А. Д. // ДАН. 2008. T. 421. № 5. С. 709–712.
- Rousseaux C.G., Greene S.F. // J. Recept. Signal. Trans. 2016. V. 36. Р. 327–388.
- Hellewell S.B., Bruce A., Feinstein G., et al. // Eur. J. Pharmacol. 1994. V. 268. P. 9–18.
- Cobos E.J., Entrena J.M., Nieto F.R., et al. // Curr. Neuropharmacol. 2008. V. 6. P. 344–366.
- Su T.-P., Hayashi T., Maurice T., et al. // Trends Pharmacol. Sci. 2010. V. 31. P. 557–566.
- Мельницкая А.В., Крутецкая З.И., Бутов С.Н., Крутецкая Н.И., Антонов В.Г. В сб. “Актуальные вопросы биологической физики и химии БФФХ-2017”. Севастополь: Севастопол. гос. ун-т, 2017. С. 272–275.
- Itzhak Y., Ruhland M., Krahling H. // Neuropharmacology. 1990. V. 29. P. 181–184.
- Cobos E.J., Del Pozo E., Baeyens J.M. // J. Neurochem. 2007. V. 102. P. 812–825.
- Carnally S.M., Johannessen M., Henderson R.M., et al. // Biophys. J. 2010. V. 98. Р. 1182–1191.
- Herrera Y., Katnik C., Rodriguez J.D., et al. // J. Pharmacol. Exp. Ther. 2008. V. 327. Р. 491–502.
- Firsov D., Robert-Nicoud M., Gruender S., et al. // J. Biol. Chem. 1999. V. 274. P. 2743–2749.
- Boldyrev A.A., Bulygina E.R. // Ann. N.Y. Acad. Sci. 1997. V. 834. Р. 666–668.
Supplementary files
